Search Results 341-350 of 24045 for Ovary
The purpose of this Phase 1a/1b study of SC-003 in patients with platinum-resistant/refractory ovarian cancer is to characterize the safety and tolerability ...
... ovary are not produced. So GnRH, the gonadotropic releasing hormone that is produced, triggers the follicular stimulating hormone, and the luteinizing ...
About this study. Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy. Participation eligibility.
Giving carboplatin and gemcitabine with or without ATR kinase inhibitor VX-970 may work better in treating ovarian, primary peritoneal, or fallopian tube cancer ...
... . VID-20464306. Home; New Hope for Ovarian Cancer. Double your impact on cancer! Give Now. Make a gift before July 31 and it can be doubled in impact ...
Mayo Clinic researcher Carrie L. Langstraat, M.D., studies ovarian cancer outcomes and the use of AI to more accurately distinguish between cancerous and ...
Masculinizing hormone therapy involves taking the male hormone testosterone. It stops menstrual cycles and lowers the ovaries' ability to make estrogen.
The purpose of this study is to investigate how abrupt loss of ovarian hormones following bilateral oophorectomy affects overall aging, physical performance, ...
It is not yet known whether gemcitabine hydrochloride with or without AZD1775 may be an effective treatment for recurrent ovarian, primary peritoneal, or ...
Niraparib is used as first-line maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.